Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
- Conditions
- Renal Impairment
- Interventions
- Drug: PF-07321332/ritonavir
- Registration Number
- NCT04909853
- Lead Sponsor
- Pfizer
- Brief Summary
This is a Phase 1, non-randomized, open-label, 2-part study to investigate the effect of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF-07321332 in combination with the PK boosting agent ritonavir. Participants will be selected and categorized into normal renal function or renal impairment groups based on their estimated glomerular filtration rate. Part 1: will be conducted in approximately 24 participants (approximately 8 per group) with stable mild or moderate renal impairment and a control group of participants with normal renal function. Part 2 will be conducted in approximately 8 participants with stable severe renal impairment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
-
Male or female, non-smoker and/or light smoker
-
Have a diagnosis of stable renal impairment
-
Meet the following estimated glomerular filtration rate (eGFR) criteria during the screening period (based on 2 Screening visits) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation:
- Mild renal impairment: eGFR between 60 - 89 mL/min.
- Moderate renal impairment: eGFR ≥30 mL/min and <60 mL/min.
- Severe renal impairment: eGFR <30 mL/min, but not requiring hemodialysis.
- Normal renal function: eGFR ≥90 mL/min
Renal impairment participants:
- Any form of renal impairment except acute nephritic syndrome (participants with history of previous nephritic syndrome but in remission can be included).
- Good general health commensurate with the population with chronic kidney disease (renal impairment).
- Stable concomitant drug regimen for the management of individual participant's medical conditions, so long as they are considered necessary for the welfare of the study participants (eg, standard therapy for underlying diseases), and are not contraindicated with study drug, and are unlikely to interfere with the PK of study drug.
Healthy participants with normal renal function:
-
No clinically relevant abnormalities identified by a detailed medical history, full physical examination, including temperature, blood pressure (BP) and pulse rate measurement, 12 lead ECG and clinical laboratory tests.
-
Demographically comparable to the group of participants with impaired renal function.
- Each participant's body weight within ±15 kg of the mean body weight of renal impairment group.
- Each participant's age within ±10 years of the mean age of the renal impairment group.
- Positive test result for SARS-CoV-2 infection at the time of screening or Day -1.
- History of HIV infection, hepatitis B, or hepatitis C; positive testing at screening for HIV, HBsAg, HBcAb, or HCVAb. As an exception a positive HBsAb test due to Hepatitis B vaccination is allowed.
- Renal transplant recipients.
- Urinary incontinence without catheterization
- Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, cholecystectomy, appendectomy).
- Participants who have been vaccinated with COVID-19 vaccines within the past 2 weeks of dosing, or are to be vaccinated with these vaccines at any time during the study.
- A positive urine drug test, for illicit drugs, at Screening
- aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level >2 × upper limit of normal (ULN)
- Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is≤ ULN.
- History of sensitivity reactions to ritonavir or any of the formulation components of PF 07321332 or ritonavir.
- Female participants of childbearing potential who are unwilling or unable to use highly effective methods of contraception as outlined in Section 5.3.4 for the duration of the study and for at least 28 days after the administration of investigational product, pregnant female participants, female participants planning to become pregnant during the duration of the study until 28 days after the administration of investigational product, breastfeeding female participants.
Renal impairment participants:
- Participants requiring hemodialysis and/or peritoneal dialysis
- Participants with other clinically significant disease that may affect the safety of the participant or that may affect the PK of PF-07321332. Participants with any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephrotic.
Healthy participants with normal renal function:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Screening supine BP >140 mm Hg (systolic) or >90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is >140 mm Hg (systolic) or >90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-07321332 PF-07321332/ritonavir PF 07321332/ritonavir
- Primary Outcome Measures
Name Time Method Maximum Observed Plasma Concentration (Cmax) of PF-07321332 Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose on Day 1 Area Under the Plasma Concentration-time Profile From Time Zero (0) to Extrapolated Infinite Time (AUCinf) of PF-07321332 Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose on Day 1 AUCinf was calculated by AUClast + (Clast/kel). AUClast was the area under the plasma concentration-time profile from time 0 to the time of Clast. Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Amount of PF-07321332 Excreted Unchanged in Urine Over 48 Hours (Ae48) Part 1 and Part 2: 0 to 48 hours post dose on Day 1 Total amount of unchanged drug excreted in the urine over 48 hours.
Renal Clearance (CLr) of PF-07321332 Part 1 and Part 2: 0 to 48 hours post dose on Day 1 Renal clearance was calculated as total amount of unchanged drug excreted in the urine over 48 hours (Ae48) divided by area under the plasma concentration-time profile from time 0 to 48 hours post dose.
- Secondary Outcome Measures
Name Time Method Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Emergent Treatment Related AEs and Treatment Emergent Treatment Related SAEs Part 1 and Part 2: Day -1 up to maximum of 35 days after last dose (maximum of 38 days) An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that, at any dose resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent was considered serious; other important medical events. TEAEs were events occurred following start of treatment or increased in severity up to maximum of 35 days after last dose. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness was judged by investigator.
Number of Participants With Clinical Laboratory Abnormalities Part 1 and Part 2: Day -1 up to maximum of 35 days after last dose (maximum of 38 days) The hematology, clinical chemistry and urinalysis tests were included in the laboratory examination. The criteria for hematology evaluation included hemoglobin less than (\<) 0.8\*lower limit of normal (LLN), hematocrit \<0.8\*LLN, erythrocytes \<0.8\*LLN, erythrocyte mean corpuscular hemoglobin \<0.9\*LLN and lymphocytes \<0.8\*LLN. The criteria for clinical chemistry evaluation included neutrophils \<0.8\*LLN, eosinophils greater than (\>) 1.2\* upper limit of normal (ULN), monocytes \>1.2\*ULN, urea nitrogen \>1.3\*ULN, creatinine \>1.3\*ULN, urate \>1.2\*ULN, potassium \>1.1\*ULN and bicarbonate \<0.9\*LLN. The criteria for urinalysis evaluation included thyrotropin \>1.2\*ULN, glucose \>1.5\*ULN, fibrinogen \>1.25\*baseline, ketones greater than or equal to (\>=) 1, urine protein \>=1, nitrite \>=1 and leukocyte esterase \>=1.
Number of Participants With Clinically Significant Vital Signs Abnormalities Part 1 and Part 2: Day -1 up to maximum of 35 days after last dose (maximum of 38 days) Supine blood pressure, pulse rate, respiratory rate and oral temperature were evaluated in vital signs examination. Clinical significance was judged by investigator.
Number of Participants With Clinically Significant Findings in Physical Examination Part 1 and Part 2: Day -1 up to maximum of 35 days after last dose (maximum of 38 days) A complete physical examination included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by investigator.
Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities Part 1 and Part 2: Day -1 up to maximum of 35 days after last dose (maximum of 38 days) A standard 12-lead ECGs utilizing limb leads (with a 10 second rhythm strip) were collected using an ECG machine that automatically calculates the heart rate and measures PR, QT, and QTc intervals and QRS complex. All scheduled ECGs were performed after the participant had rested quietly for at least 5 minutes in a supine position. Clinical significance was judged by investigator.
Plasma Concentration of PF-07321332 at 12 Hours Post Dose (C12) Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 Plasma Concentration of PF-07321332 at 24 Hours Post Dose (C24) Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose on Day 1 Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07321332 Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose on Day 1 Tmax was observed directly from data as time of first occurrence.
Area Under the Plasma Concentration-time Profile From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUClast) of PF-07321332 Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose on Day 1 Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration was determined by linear/log trapezoidal method.
Apparent Clearance (CL/F) of PF-07321332 From Plasma Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose on Day 1 Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma. CL/F was calculated by Dose/AUCinf.
Apparent Volume of Distribution (Vz/F) of PF-07321332 Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose on Day 1 Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. Vz/F was calculated by dose/(AUCinf\*kel). kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Terminal Elimination Plasma Half-life (t1/2) of PF-07321332 Part 1 and Part 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose on Day 1 t1/2 was calculated by Loge(2)/kel. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Trial Locations
- Locations (5)
Orange County Research Center
🇺🇸Tustin, California, United States
Genesis Clinical Research, LLC
🇺🇸Tampa, Florida, United States
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics
🇺🇸Miami, Florida, United States
University of Miami Division of Clinical Pharmacology
🇺🇸Miami, Florida, United States
Prism Research LLC dba Nucleus Network
🇺🇸Saint Paul, Minnesota, United States